Alina Cherkas

Alina Cherkas


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2022 in Medical Immunology (Russia)
Verified
Journal Article
Open access
PDF file
SUStanislav Urazov
Stanislav Urazov
Alexander N ChernovAlexander N Chernov
Alexander N Chernov
ACAlina Cherkas
Alina Cherkas
ABA. V. Boikov
A. V. Boikov
OGO. S. Glotov
O. S. Glotov
SSS. G. Shcherbak
S. G. Shcherbak
Secretory phospholipases A2 (sPLA2) represent a large superfamily of enzymes with a molecular weight of 14-19 kDa, including 15 groups and more than 30 isoforms belonging to four types: secretory (sPLA2), cytosolic (cPLA2), calcium-independent (iPLA2) and lipoprotein-associated phospholipase A2 (LP-PLA2, PAF-AH). Eleven species of secretory sPLA2s (IB, IIA, IIC, IID, IIE, IIF, III, V, X, XIIA, and XIIB) have been found in mammals, performing versatile functions and participating in the pathogenesis of a wide range of diseases. On the one hand, sPLA2 may promote elimination of damaged, apoptotic cells by hydrolyzing membrane phospholipids, and exerts a strong bactericidal and antiviral properties, including pronounced effects against antibiotic-resistant strains of microorganisms. In this regard, the use of sPLA2 may represent a new strategy for the treatment of bacterial and viral infections. Moreover, due to the action of sPLA2 on its substrates, a number of biologically active molecules (arachidonic, lysophosphatidic acids, lysophospholipids, fatty acids, prostaglandins, leukotrienes, thromboxanes) are formed, which provide strong inflammatory, detergent, coagulating effects and increase vascular permeability. This pro-inflammatory role of sPLA2 may explain its increase levels and activity in cardiovascular, respiratory, autoimmune, metabolic, oncological, bacterial and viral disorders. The review article presents a classification of sPLA2 isoforms, their substrates, regulatory factors, biological significance, and mechanisms of their strong bactericidal, virucidal, and pro-inflammatory activity in the heart and lung disorders, autoimmune, metabolic, bacterial, and viral diseases. In particular, the mechanisms of the selective action of sPLA2 against Gram-positive and Gram-negative microorganisms are discussed. We consider diagnostic and prognostic significance, correlations between elevated levels and activity of sPLA2 and distinct clinical symptoms, severity and outcome in the patients with coronary heart disease (CAD), acute myocardial infarction (AMI), atherosclerosis, acute inflammatory lung injury (ALI), respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, bronchial asthma, bacterial infections, septicemia and viral (COVID-19) infections. The opportunity of using sPLA2 as a biomarker of the severity and outcome of patients with chronic obstructive pulmonary disease, bacterial infections, sepsis and viral infections, including COVID-19, is also considered.

5 February 2023
Verified
Book Chapter
Closed access
PDF file
NANikolay Abramov
Nikolay Abramov
GZGeorgiy Zagorodny
Georgiy Zagorodny
TKTatiana Kareva
Tatiana Kareva
NKNadezhda Kornilova
Nadezhda Kornilova
ASAleksandr Stakhiev
Aleksandr Stakhiev
ACAlina Cherkas
Alina Cherkas

9 November 2024
Verified
Book Chapter
Closed access
PDF file
MKMarina S. Kogan
Marina S. Kogan
DGDaria A. Gavrilik
Daria A. Gavrilik
ARAnna V. Rubtsova
Anna V. Rubtsova
ENElizaveta R. Nikulina
Elizaveta R. Nikulina
ACAlina Cherkas
Alina Cherkas
MBMarina Bolsunovskaya
Marina Bolsunovskaya

16 November 2022
Verified
Book Chapter
Closed access
PDF file
NANikolay Abramov
Nikolay Abramov
GZGeorgiy Zagorodny
Georgiy Zagorodny
TKTatiana Kareva
Tatiana Kareva
NKNadezhda Kornilova
Nadezhda Kornilova
ASAleksandr Stakhiev
Aleksandr Stakhiev
ACAlina Cherkas
Alina Cherkas